English | 繁體

Search in the results

UM

Browse/Search Results:  1-1 of 1 Help

Selected(0)Clear Items/Page:    Sort:
Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma Journal article
Zou, Huimin, Lai, Yunfeng, Chen, Xianwen, Ung, Carolina Oi Lam, Hu, Hao. Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma[J]. Therapeutic Advances in Gastroenterology, 2025, 18, 1-13.
Authors:  Zou, Huimin;  Lai, Yunfeng;  Chen, Xianwen;  Ung, Carolina Oi Lam;  Hu, Hao
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:3.9/4.0 | Submit date：2025/01/22
Camrelizumab  Cost-effectiveness Analysis  Hepatocellular Carcinoma  Partitioned Survival Model  Rivoceranib